Comparative Efficacy Of Cabozantinib And Ramucirumab After Sorafenib For Patients With Advanced Hepatocellular Carcinoma And Afp >= 400 Ng/Ml

HEPATOLOGY(2020)

引用 8|浏览24
暂无评分
摘要
Cabozantinib (CAB) and ramucirumab (RAM) are approved for the treatment of adults with hepatocellular carcinoma (HCC) following sorafenib (SOR); RAM is restricted for use in patients with a serum α-fetoprotein (AFP) ≥400 ng/ml. The matching-adjusted indirect comparison (MAIC) evaluated the efficacy and safety of both agents after SOR in HCC patients with AFP≥400 ng/ml.
更多
查看译文
关键词
advanced hepatocellular carcinoma,hepatocellular carcinoma,sorafenib,cabozantinib,ramucirumab
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要